Recall: Quinapril
Jan. 2023Pharmacy Updates
Lupin Pharmaceuticals Inc. has recalled four lots of Quinapril Tablets because they contain of a nitrosamine impurity, N-Nitroso-Quinapril, observed in recent testing above the Acceptable Daily Intake (ADI) level. Such impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time. Read the full text of the Quinapril recall.
Recent Announcements
Clinical workflow changes through Epic®
Changes are coming for network providers that utilize Provider OnLine to submit specific information to UPMC Health Plan. Select activities that were previously completed in Provider OnLine will now transition to UPMC Health Plan Tapestry Link.Sep. 2026Important Notices
CME Webinar: Lifestyle Medicine in Practice: Evidence‑Based Strategies for Chronic Disease Care
Please join us for a live, CME-accredited webinar on Wednesday, Sept. 23 from noon to 1 p.m., that will provide an overview on lifestyle medicine. Participants will learn how to integrate six core domains—nutrition, physical activity, sleep, stress management, avoidance of risky substances, and social connection—into routine care using practical tools such as brief counseling, motivational interviewing, and team-based strategies.Sep. 2026Education/Webinars
Voluntary nationwide recall: Thyroid (Vitruvias – August 2026)
Vitruvias Therapeutics Inc. is recalling one lot, lot 504950, of Thyroid Tablets, USP 30 mg. Thyroid Tablet is used to treat hypothyroidism (underactive thyroid).Sep. 2026Pharmacy Updates